TIDMAGL
Angle PLC
05 June 2023
For immediate release 05 June 2023
ANGLE plc ("the Company")
ANGLE STRENGTHENS MANAGEMENT TEAM WITH SENIOR APPOINTMENTS
Brett Swansiger joins as Chief Commercial Officer
Karen Miller PhD joins as Chief Scientific Officer
ANGLE plc (AIM: AGL; OTCQX: ANPCY), a world-leading liquid
biopsy company, is delighted to announce the appointments of Brett
Swansiger as Chief Commercial Officer (CCO) and Karen Miller PhD as
Chief Scientific Officer (CSO). The addition of these highly
skilled and experienced leaders will further enhance ANGLE's
management team and support the Company in realising its commercial
potential.
Brett brings over 20 years of commercial leadership,
international business development, business-to-business sales and
US managed care contracting experience within the molecular
diagnostic and pharmaceutical industries. Most recently, Brett was
CCO at DxTerity Diagnostics where he built out the commercial
organisation, established new business relationships and initiated
payer strategies. Brett began his life sciences career at Bristol
Myers Squibb before moving into senior commercial positions at
Prometheus Laboratories, Agendia Inc, and MDxHealth. Brett is based
in the United States and is responsible for managing pharma and
clinical services sales, building corporate partnerships globally,
and for guiding US research and clinical product sales and payer
engagement. He also supports the products business teams
responsible for direct sales of products and sales through ANGLE's
growing distributor network.
Karen has over 30 years of experience in the pharmaceutical
industry with an extensive background in drug discovery and
clinical development as well as in-depth knowledge of molecular
analysis techniques used for cancer analysis in a wide range of
indications with multiple modalities. She brings a strong network
of relationships within the pharmaceutical and companion diagnostic
industries. Karen was most recently CSO at Ixaka where she led
research strategy, guided major projects through to the clinic and
participated in partnership and licensing activities. Previous
experience includes senior executive positions with Vertex
Pharmaceuticals, UCB Pharma, GlaxoSmithKline and Adaptimmune. At
ANGLE, Karen is responsible for external interactions with pharma
customers, medtech partner companies and laboratory customers to
drive the widespread adoption of the Parsortix system as well as
providing overall scientific leadership for the Company.
ANGLE Founder and Chief Executive, Andrew Newland,
commented:
"I am delighted to be able to welcome these two highly
accomplished individuals to the ANGLE management team. Brett and
Karen bring valuable skills and networks that will play a key role
in helping us deliver on our strategic and commercial objectives. I
look forward to working closely with them as we continue to build
commercial momentum."
For further information:
ANGLE plc +44 (0) 1483 343434
Andrew Newland, Chief Executive
Ian Griffiths, Finance Director
Andrew Holder, Head of Investor Relations
Berenberg (NOMAD and Joint Broker)
Toby Flaux, Ciaran Walsh, Milo Bonser +44 (0) 20 3207 7800
Jefferies (Joint Broker)
Thomas Bective, Shaam Vora +44 (0) 20 7029 8000
FTI Consulting
Simon Conway, Ciara Martin +44 (0) 203 727 1000
Matthew Ventimiglia (US) +1 (212) 850 5624
For Frequently Used Terms, please see the Company's website on
https://angleplc.com/investor-relations/glossary/
Notes for editors
About ANGLE plc www.angleplc.com
ANGLE is a world leading liquid biopsy company with
sample-to-answer solutions. ANGLE's proven patent protected
circulating tumor cell (CTC) harvesting technology is known as the
Parsortix(R) system.
ANGLE's Parsortix(R) system is FDA cleared for its intended use
in metastatic breast cancer and is currently the first and only FDA
cleared medical device to harvest intact circulating cancer cells
from blood.
Intended use
The Parsortix(R) PC1 system is an in vitro diagnostic device
intended to enrich circulating tumor cells (CTCs) from peripheral
blood collected in K(2) EDTA tubes from patients diagnosed with
metastatic breast cancer. The system employs a microfluidic chamber
(a Parsortix cell separation cassette) to capture cells of a
certain size and deformability from the population of cells present
in blood. The cells retained in the cassette are harvested by the
Parsortix PC1 system for use in subsequent downstream assays. The
end user is responsible for the validation of any downstream assay.
The standalone device, as indicated, does not identify, enumerate
or characterize CTCs and cannot be used to make any
diagnostic/prognostic claims for CTCs, including monitoring
indications or as an aid in any disease management and/or treatment
decisions.
The Parsortix PC1 system enables a liquid biopsy (a simple blood
test) to be used to provide the circulating tumor cells from
metastatic breast cancer patients to the user in a format suitable
for multiple types of downstream analyses. The system is based on a
microfluidic device that captures cells based on a combination of
their size and compressibility. The system is epitope independent
and can capture all phenotypes of CTCs (epithelial, mesenchymal and
EMTing CTCs) as well as CTC clusters in a viable form (alive). CTCs
harvested from the system enable a complete picture of a cancer to
be seen; as being an intact cell they allow DNA, RNA and protein
analysis as well as cytological and morphological examination and
may provide comparable analysis to a tissue biopsy in metastatic
breast cancer. Because CTC analysis is a non-invasive process,
unlike tissue biopsy, it can be repeated as often as needed. This
is important because cancer develops and changes over time and
there is a clear medical need for up-to-date information on the
status of a patient's tumor. In addition, the live CTCs harvested
by the Parsortix system can be cultured, which offers the potential
for testing tumor response to drugs outside the patient.
The Parsortix technology is the subject of 26 granted patents in
Europe, the United States, China, Australia, Canada, India, Japan
and Mexico with three extensive families of patents are being
progressed worldwide.
In the United States, the Parsortix(R) PC1 system has received a
Class II Classification from FDA for use with metastatic breast
cancer patients. FDA clearance is seen as the global gold standard.
ANGLE's Parsortix system is the first ever FDA cleared system for
harvesting CTCs for subsequent analysis. ANGLE has applied the IVD
CE Mark to the same system for the same intended use in Europe.
ANGLE has also completed three separate 200 subject clinical
studies under a programme designed to develop an ovarian cancer
pelvic mass triage test, with the results showing best in class
accuracy (AUC-ROC) of 95.4% with sensitivity of 90% and specificity
of 93%. This excellent clinical result demonstrates the utility of
cells harvested by the Parsortix system, which the Company believes
is the "best sample" for liquid biopsy analysis as it recovers
intact, living cancer cells that are involved in the progression of
the disease providing prospective information.
ANGLE has established formal collaborations with world-class
cancer centres and major corporates such as Abbott, Philips and
QIAGEN, and works closely with leading CTC translational research
customers. These Key Opinion Leaders (KOLs) are working to identify
applications with medical utility (clear benefit to patients), and
to secure clinical data that demonstrates that utility in patient
studies. The body of evidence as to the benefits of the Parsortix
system is growing rapidly from our own clinical studies in
metastatic breast cancer and ovarian cancer and also from KOLs with
80 peer-reviewed publications and numerous publicly available
posters from 35 independent cancer centres, available on our
website.
ANGLE has established clinical services laboratories in the UK
and the United States to accelerate commercialisation of the
Parsortix system and act as demonstrators to support product
development. The laboratories offer services globally to
pharmaceutical and biotech customers for use of Parsortix in cancer
drug trials and, once the laboratories are accredited and tests
validated, will provide Laboratory Developed Tests (LDTs) for
patient management.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAKZLFBXQLZBBV
(END) Dow Jones Newswires
June 05, 2023 02:00 ET (06:00 GMT)
Angle (LSE:AGL)
Historical Stock Chart
From Apr 2024 to May 2024
Angle (LSE:AGL)
Historical Stock Chart
From May 2023 to May 2024